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Abstract
Introduction Tamoxifen (TAM) is an antiestrogen widely used in
the treatment and prevention of breast cancer in women. One of
the major mechanisms of metabolism of TAM and one of its
major active metabolites, 4-hydroxytamoxifen (4-OH-TAM), is via
glucuronidation. In the present study, the glucuronidating
activities of three common variant isoforms encoded by the
human UDP-glucuronosyltransferase (UGT) 1A4 gene were
examined against TAM, trans-4-OH-TAM and cis-4-OH-TAM.
Methods HPLC was used to detect glucuronide conjugates in
microsomes from UGT1A4-overexpressing HK293 cells. The
UGT1A4 wild-type cDNA was synthesized by RT-PCR using
normal human liver total RNA. The UGT1A424Thr/48Leu  and
UGT1A424Pro/48Val  variants were generated by site-directed
mutagenesis of the pcDNA3.1/V5-His-TOPO plasmid
expressing wild-type UGT1A424Pro/48Leu. Levels of UGT1A4
expression in UGT-overexpressing cell lines were measured by
western blot analysis.
Results Microsomes from wild-type UGT1A424Pro/48Leu-
overexpressing HK293 cells exhibited significant levels of
activity against TAM, trans-4-OH-TAM and cis-4-OH-TAM,
forming exclusively the tamoxifen quaternary ammonium
glucuronide (TAM-N+-glucuronide) and the 4-hydroxytamoxifen
quaternary ammonium glucuronides (trans-4-OH-TAM-N+-
glucuronide and cis-4-OH-TAM-N+-glucuronide) with apparent
Km values of 2.0 µM, 2.2 µM, and 2.1 µM, respectively. Higher
glucuronidation activities were found by kinetic analysis for
microsomes from the variant UGT1A424Pro/48Val-overexpressing
cell line as compared with microsomes from wild-type
UGT1A424Pro/48Leu-overexpressing cells against TAM and
against both the trans  and  cis  isomers of 4-OH-TAM. A
significantly (P < 0.02) lower Km value (~1.6-fold to 1.8-fold)
was observed for both 4-OH-TAM isomers, while a near-
significant (P = 0.053) decrease in Km was observed for TAM for
the UGT1A424Pro/48Val  variant as compared with wild-type
UGT1A4. The Vmax/Km ratio for the UGT1A424Pro/48Val variant
was significantly (P ≤ 0.005) higher than that observed for the
wild-type UGT1A4 isoform for both the trans and cis isomers of
4-OH-TAM after normalization for UGT1A4 expression by
western blotting. No significant effect on enzyme kinetics was
observed for the UGT1A424Thr/48Leu variant against either isomer
of 4-OH-TAM or with TAM.
Conclusion These data suggest that the UGT1A4 codon 48
Leu>Val polymorphism significantly alters glucuronidation rates
against TAM and its active hydroxylated metabolites, and that
this polymorphism may play an important role in individual
pharmacological response to TAM therapy.
DMEM = Dulbecco's modified Eagle's medium; HPLC = high-performance liquid chromatography; Km = Michaelis-Menten equilibrium constant; LC–
MS = liquid chromatography–mass spectrometry; Leu = leucine; 4-OH-TAM = 4-hydroxytamoxifen; 4-OH-TAM-N+-glucuronide = 4-hydroxytamoxifen 
quaternary ammonium glucuronide; TAM = tamoxifen; TAM-N+-glucuronide = tamoxifen quaternary ammonium glucuronide; PCR = polymerase chain 
reaction; Pro = proline; RT = reverse transcriptase; Thr = threonine; UDPGA = UDP-glucuronic acid; UGT = UDP-glucuronosyltransferase; Val = 
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Introduction
Tamoxifen (TAM) (1- [4-(2-dimethylaminoethoxy)-phenyl]-1,2-
diphenylbut-1(Z)-ene) is a nonsteroidal antiestrogen com-
monly used for the treatment and prevention of estrogen-
dependent breast cancer [1-4]. Adjuvant TAM treatment
increases recurrence-free survival and overall survival in breast
cancer patients with hormone receptor-positive tumors irre-
spective of their nodal status, menopausal status or age [5]. In
addition to its antiestrogenic properties, which have been
related to symptoms such as hot flashes, vaginal bleeding and
pruritus vulvae [2,6], TAM also has partial estrogen-agonistic
effects that may be linked to reduced risk for ischemic heart
disease and osteoporosis [7,8], but may also increase the risk
for endometrial cancer [9,10] and venous thromboembolism
[11]. Although TAM is generally well tolerated, there is signifi-
cant interindividual variability in the clinical efficacy of TAM as
well as in the toxicities of TAM. For instance, about 30% of
patients acquire TAM resistance and relapse [12]. In addition,
the relative risk of endometrial cancers in patients treated with
TAM is estimated to be twofold to threefold that of controls,
the risk increasing with both the duration of and cumulative
dose of TAM treatment [10,13-15].
The mechanisms underlying variability in response to TAM and
to TAM-related toxicities remain obscure. Since there is com-
pelling evidence that TAM is converted to antiestrogenic
metabolites more potent than TAM itself, one hypothesis is
that altered patterns of metabolism of TAM and/or its primary
metabolites might contribute to this interindividual variability.
TAM is activated predominantly via cytochrome P450-medi-
ated pathways into several metabolites after oral administra-
tion, including the hydroxylated TAM metabolites, 4-
hydroxytamoxifen (4-OH-TAM) and 4-hydroxy-N-desmethyl-
TAM (endoxifen). Since both trans-4-OH-TAM and endoxifen
exhibit up to 100-fold the levels of antiestrogenic activity com-
pared with TAM and other TAM metabolites [16-21], it is
thought they may be the major contributors to TAM's antiestro-
genic properties. While cis-4-OH-TAM is thought to be prima-
rily an estrogen agonist, this isomer exhibits significant
antiestrogenic activity in vitro when in the presence of estra-
diol [22-24].
An important route of elimination and detoxification of TAM
and its metabolites is via glucuronidation. TAM is excreted pre-
dominantly through the bile, a process largely facilitated by
TAM conjugation to glucuronic acid during the glucuronidation
process [25], and TAM glucuronides have been identified in
the urine of TAM-treated patients [26]. Most of the 4-OH-TAM
in the bile of TAM-treated patients was found as a glucuronide
conjugate [25,27]. The fact that TAM metabolites are found in
their unconjugated form in feces is probably due to β-glucuro-
nidase-catalyzed deglucuronidation within the microflora that
colonize within the small intestine [25]. TAM glucuronide con-
jugates have been identified in the serum of TAM-treated
patients [25,27], and it has been suggested that glucuronida-
tion within target tissues such as the adipose tissue of the
breast may also be important in terms of TAM metabolism and
overall TAM activity [28].
One of the major UDP-glucuronosyltransferases (UGTs)
involved in the glucuronidation of TAM and its metabolites is
the hepatic enzyme UGT1A4 [29,30], which catalyzes the for-
mation of a quarternary ammonium-linked glucuronide with
TAM's N, N-dimethylaminoalkyl side chain [30]. This pattern of
ammonium-linked glucuronidation is consistent with
UGT1A4's glucuronidation activity against primary, secondary
and tertiary amines present in a variety of carcinogenic com-
pounds, androgens, progestins and plant steroids [31-34].
Two unlinked missense polymorphisms were identified at
codon 24 (Pro>Thr) and codon 48 (Leu>Val) within the
UGT1A4 gene [35,36]. The prevalence of both variant
UGT1A424Thr/48Leu and UGT1A424Pro/48Val alleles approached
0.10 in Caucasian populations [35,36]. The codon 24 poly-
morphism was linked to altered glucuronidation activity
against the tobacco-specific nitrosamine, 4(methylnitro-
samino)1(3pyridyl)1butanol [36], while the UGT1A448Val vari-
ant was associated with decreased rates of glucuronidation
after transient transfection into cell lines in vitro [35].
The aim of the present study was to characterize UGT1A4-
induced glucuronidation of TAM, trans-4-OH-TAM and cis-4-
OH-TAM, and to examine whether missense variants in the
UGT1A4 gene alter activity against TAM and its hydroxylated
metabolites in vitro.
Materials and methods
Chemicals and materials
UDP-glucuronic acid (UDPGA), trans-TAM, trans-4-OH-TAM
(98% pure), trans-4-OH-TAM:cis-4-OH-TAM (70:30% ratio),
alamethicin, β-glucuronidase, anticalnexin antibody and bovine
serum albumin were purchased from Sigma-Aldrich (St Louis,
MO, USA). HPLC-grade ammonium acetate and acetonitrile
were purchased from Fisher Scientific (Pittsburgh, PA, USA)
and were used after filtration. DMEM, Dulbecco's phosphate-
buffered saline (minus calcium chloride and magnesium chlo-
ride), fetal bovine serum, penicillin-streptomycin and geneticin
(G418) were purchased from Gibco (Grand Island, NY, USA).
The Platinum® Pfx DNA polymerase and the pcDNA3.1/V5-
His-TOPO mammalian expression vector were obtained from
Invitrogen (Carlsbad, CA, USA), while the restriction enzymes
DpnI and StuI were purchased from New England Biolabs
(Beverly, MA, USA). The BCA protein assay kit was purchased
from Pierce (Rockford, IL, USA) while the QIAEX® II gel extrac-
tion kit was purchased from Qiagen (Valencia, CA, USA). The
human UGT1A western blotting kit and anti-UGT1A antibody
were purchased from Gentest (Woburn, MA, USA). All otherAvailable online http://breast-cancer-research.com/content/8/4/R50
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chemicals used were purchased from Fisher Scientific (Pitts-
burgh, PA, USA) unless otherwise specified.
Tissues
A description of the normal human liver tissue specimens used
for these studies was presented previously [36]. Briefly, tis-
sues were quick-frozen at -70°C within 2 hours postsurgery.
Liver microsomes were prepared through differential centrifu-
gation as previously described [37] and were stored (10–20
mg protein/ml) at -70°C. Microsomal protein concentrations
were measured using the BCA assay (Pierce). All protocols
involving the analysis of tissue specimens were approved by
the institutional review board at the Penn State College of
Medicine and in accordance with assurances filed with and
approved by the United States Department of Health and
Human Services.
UGT1A4 cloning
The UGT1A4 wild-type cDNA was synthesized by RT-PCR
using normal human liver total RNA and was inserted into the
pcDNA3.1/V5-His-TOPO plasmid. The sense and antisense
primers used for RT-PCR were UGT1A4s1 (5'-ACAGT-
CAGCTGTCGGTGGC-3', corresponding to -29 to -11 rela-
tive to the UGT1A4 translation start site; GenBank accession
number NM007120) and UGT1A4as1 (5'-ATTTTACCTTATT-
TCCCACCC-3', corresponding to +1611 to +1631 relative
to the UGT1A4 translation start site), respectively.
Incubations were performed in a GeneAmp 9700 thermocy-
cler (Applied Biosystems, Foster City, CA, USA) as follows:
one cycle at 94°C for 2 minutes, 41 cycles at 94°C for 30 sec-
onds, at 55°C for 30 seconds and at 72°C for 2 minutes, fol-
lowed by a final cycle of 7 minutes at 72°C. The PCR product
(1662 base pairs) was purified after electrophoresis in 1.5%
agarose using the QIAEX® II gel extraction kit (Qiagen), and
was subsequently subcloned into the pcDNA3.1/V5-His-
TOPO mammalian expression vector using standard method-
ologies.
Confirmation of insert orientation was performed by restriction
enzyme digestion, and UGT1A4 sequences were confirmed
by dideoxy sequencing of the entire PCR-amplified UGT1A4
cDNA product (performed at the Molecular Biology Core
Facility at Penn State University College of Medicine) using
two vector primers (T7 and BGH; IDT, Coralville, IA, USA) and
one internal sense primer (UGT1A4s2 – 5'-GAAGGAATTT-
GATCGCGTTAC-3', corresponding to nucleotides +258 to
+278 relative to the UGT1A4 translation start site). The
cloned UGT1A4 insert was compared with that described in
GenBank and was confirmed to be 100% homologous to the
wild-type UGT1A424Pro/48Leu  sequence (accession number
NM007120).
Generation of UGT1A4 variants, overexpressing cell lines 
and cell microsome preparation
The UGT1A424Thr/48Leu and UGT1A424Pro/48Val variants were
generated by site-directed mutagenesis of the pcDNA3.1/V5-
His-TOPO plasmid expressing wild-type UGT1A424Pro/48Leu.
The primers used to change codon 24 from Pro to Thr were
UGT1A4c24F (5'-CAGTGTCCAGACCTGGGCTGA-
GAGTG-3') and UGT1A4c24R (5'-CACTCTCAGCCCAG-
GTCTGGACACTG-3'), both primers corresponding to
nucleotides +60 to +85 relative to the UGT1A4 translation
start site (mutated base indicated in bold). The primers used
to change codon 48 from Leu to Val were UGT1A4c48F (5'-
CTCAGCATGCGGGAGGCCGTGCGGGAGCTCCATGC-
3') and UGT1A4c48R (5'-GCATGGAGCTCCCGCACG-
GCCTCCCGCATGCTGAG-3'), both primers corresponding
to nucleotides +124 to +158 relative to the UGT1A4 transla-
tion start site.
The products were amplified by PCR using 5 U/ml Pfx
polymerase, 1 × Pfx buffer, 2 × enhancer, 10 µM dNTPs, 500
ng template, 1 mM MgSO4 and 20 µM of each primer in a Bio-
Rad MyCycler (Hercules, CA, USA) with an initial denaturation
at 95°C for 2 minutes, followed by 25 cycles at 95°C for 30
seconds, at 65°C for 30 seconds and at 68°C for 18 minutes.
Following amplification, 20 U Dpn Irestriction enzyme was
added to each reaction and incubated for 1 hour at 37°C to
specifically digest the wild-type template DNA. The remaining
PCR product was then transformed into competent DH5α
Escherichia coli, individual colonies were isolated, and subse-
quent plasmid DNA minipreps were screened for the
UGT1A424Thr/48Leu  and UGT1A424Pro/48Val  variants using
HPY188III or StuI, respectively. The UGT1A424Thr/48Leu and
UGT1A424Pro/48Val cDNA sequences were confirmed by direct
dideoxy sequencing using the same primers used for wild-type
UGT1A4 analysis described earlier.
Human embryonic kidney fibroblast HEK293 cell lines overex-
pressing wild-type or variant UGT1A4 were generated by
standard electroporation techniques in the Bio-Rad
GenePulser Xcell using 10 µg pcDNA3.1/V5-His-TOPO/
UGT1A4 plasmid DNA with 5 × 106 HEK293 cells (in 0.5 ml)
in serum-free DMEM media, with electroporation at 250 V and
1000 µF. Following transfection, HK293 cells were grown in
5% CO2 to 80% confluence in DMEM supplemented with 4.5
mM glucose, 10 mM HEPES, 10% fetal bovine serum, 100 U/
ml penicillin, 100 µg/ml streptomycin and geneticin (700 µg/
ml medium) for the selection of geneticin-resistant clones, with
selection medium changed every 3–4 days.
Individual UGT1A4-overexpressing cell colonies were
selected and monitored for UGT1A4 expression via western
blotting analysis (described in the next section). Cell homoge-
nates were prepared by resuspending pelleted cells in Tris-
buffered saline (25 mM Tris base, 138 mM NaCl, 2.7 mM KCl,
pH 7.4) and subjecting them to three rounds of freeze-thawBreast Cancer Research    Vol 8 No 4    Sun et al.
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prior to gentle homogenization. Microsomal fractions were
prepared by centrifugation of whole cell homogenate at
10,500 rpm (9,000 × g) for 30 minutes at 4°C; the superna-
tant was collected and subsequently centrifuged at 33,500
rpm (105,000 × g) for 60 minutes at 4°C in a SW-55 Ti rotor
(Beckman, Palo Alto, CA, USA). Pellets were collected by sus-
pension in Tris-buffered saline (25 mM Tris base, 138 mM
NaCl, 2.7 mM KCl, pH 7.4) and were stored at -80°C in 100
µl aliquots. Total microsomal protein concentrations were
measured using the BCA protein assay (Pierce).
Western blot analysis
Levels of UGT1A4 expression in UGT-overexpressing cell
lines were measured by western blot analysis using the anti-
UGT1A antibody in a 1:5,000 dilution as per the manufac-
turer's instructions (Gentest), while calnexin protein levels
were assayed using a 1:5,000 dilution of the monoclonal anti-
calnexin antibody (after stripping the UGT1A4 antibody of the
same western blot using standard techniques). UGT1A4 was
detected by chemiluminescence using the SuperSignal West
Dura Extended Duration Substrate (Pierce Biotechnology,
Inc., Rockford, IL, USA). Secondary antibodies supplied with
the Dura ECL kit (anti-rabbit and anti-mouse) were used at
1:3,000. UGT1A4 levels were quantified against a known
amount of human UGT1A protein (200–300 ng, supplied in
the western blotting kit; Gentest) by densitometric analysis of
X-ray film exposures (1 s–1 min exposures) of western blots
using a GS-800 densitometer with Quantity One software
(Bio-Rad).
UGT1A4 protein levels were calculated against known titrated
quantities of UGT1A standard, with quantification made rela-
tive to the levels of calnexin observed in each lane (quantified
by densitometric analysis of western blots as already
described). Determinations of aglycone-glucuronide formation
in UGT1A4-overexpressing cell lines were calculated relative
to the levels of UGT1A4 expression in the respective cell lines.
X-ray film bands were always below densitometer saturation
levels as indicated by the densitometer software. Densitomet-
ric results were always consistent irrespective of the exposure
time. Western blot analysis and subsequent densitometric
analysis were performed in triplicate on three separate occa-
sions, using the same UGT1A4-containing cell homogenates
used for activity assays, with relative UGT1A4 protein levels
expressed as the mean of these experiments.
Glucuronidation assays
Glucuronidation activities of microsomes from human
UGT1A4-overexpressing HEK293 cells toward trans-TAM,
trans-4-OH-TAM and cis-4-OH-TAM were performed after an
initial incubation of microsomal protein (5–25 µg) with alame-
thicin (50 µg/mg protein) for 15 minutes in an ice bath. Glu-
curonidation reactions were then performed in a final reaction
volume of 100–500 µl at 37°C in 50 mM Tris–HCl (pH 7.4),
10 mM MgCl2, 4 mM UDPGA and 1–6 µM trans-TAM or trans-
4-OH-TAM, and 1–15 µM cis-4-OH-TAM. Reactions were ter-
minated by the addition of 95–495 µl cold methanol on ice.
Five microliters of propranolol (2.5 µg/ml) was added to the
final reactions, the mixtures were centrifuged for 10 minutes at
4°C at 16,100 × g, the supernatants were collected and evap-
orated, and the resulting dried sample was resuspended in
200 µl of 50% methanol. Assays with human liver microsomes
were identical except that 10 µg microsomal protein was used
in glucuronidation assays.
Samples (100 µl) were analyzed for glucuronidated TAM or for
TAM metabolites by HPLC using a Beckman Coulter System
Gold 126 Solvent Module HPLC system (Fullerton, CA, USA)
equipped with an automatic injector (model 508) and a UV
detector operated at 254 nm (model 168). HPLC was per-
formed using a 3 µ Luna C18 analytical column (4.6 mm × 150
mm; Phenomenex, Torrance, CA, USA) in series with a 5 µ
Aquasil C18 guard column (10 mm × 4 mm; Thermo Hypersil-
Keystone, Bellefonte, PA, USA). The gradient elution condi-
tions for assays with trans-4-OH-TAM or cis-4-OH-TAM were
as follows: starting with 75% buffer A (100 mM ammonium
acetate, pH 5.0) and 25% acetonitrile (5 min), a subsequent
linear gradient to 75% acetonitrile (25% buffer A) over 25 min
was performed and then maintained at 75% acetonitrile for 10
minutes. The flow rate was 0.5 ml/min. For assays with TAM,
the linear gradient was from 70% buffer A (30% acetonitrile)
to 90% acetonitrile (10% buffer A) over 30 minutes.
The amount of N+-glucuronide formed was calculated based
on the ratio of the peak area of the N+-glucuronide versus that
observed for the internal standard, propranolol. Tamoxifen
quaternary ammonium glucuronide (TAM-N+-glucuronide), the
4-hydroxytamoxifen quaternary ammonium glucuronides
(trans-4-OH-TAM-N+-glucuronide and cis-4-OH-TAM-N+-glu-
curonide), and trans-4-OH-TAM-O-glucuronide and cis-4-OH-
TAM-O-glucuronide were confirmed by 1 M NaOH hydrolysis
and sensitivity to β-glucuronidase as previously described
[34]. As controls, glucuronidation assays were regularly per-
formed using human liver microsomes (as a positive control for
glucuronidation activity) and untransfected HK293 cell
homogenate protein (as a negative control for glucuronidation
activity) as previously described [34,38]. Experiments were
always performed in triplicate in independent assays.
Liquid chromatography–mass spectrometry 
identification of 4-OH-TAM-N+-glucuronides
The predicted trans-4-OH-TAM-N+-glucuronide and cis-4-
OH-TAM-N+-glucuronide were collected after separation by
HPLC as already described and were identified by liquid chro-
matography–mass spectrometry (LC–MS) using a Shimadzu
LC-MS 2010 EV system (Shimadzu, Tokyo, Japan). The trans-
4-OH-TAM-N+-glucuronide and cis-4-OH-TAM-N+-glucuro-
nide were loaded onto a Shimadzu reverse-phase column
(Shimadzu C18, 4.6 mm × 50 mm) and were analyzed at a
flow rate of 0.2 ml/min by applying a linear mobile phase gra-Available online http://breast-cancer-research.com/content/8/4/R50
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dient from 10% to 80% (v/v) methanol/H2O over 30 minutes.
An electrospray voltage of 1.5 kV was applied using a positive
mode.
Statistical analysis
The Student t test (two-sided) was used for comparing the
rates and the kinetic values of glucuronide formation for the
UGT1A424Pro/48Leu, UGT1A424Thr/48Leu and UGT1A424Pro/48Val
variant isoforms against the different substrates examined in
this study. Kinetic constants were determined using Graphpad
Prism4 software (GraphPad Software, San Diego, CA, USA).
Results
Characterization of 4-HO-TAM glucuronides in 
microsomes from human liver and UGT1A4-
overexpressing cells
While N+-glucuronide was shown to be the only glucuronide
formed with TAM in human liver microsomes and UGT1A4-
overexpressing baculosomes [30], 4-OH-TAM O-glucuro-
nides and N+-glucuronides were formed by human liver micro-
somes. As shown in Figure 1, a HPLC assay was developed
to efficiently separate TAM and TAM metabolites from their
glucuronide conjugates.
Figure 1
HPLC analysis of 4-hydroxytamoxifen glucuronides formed by human liver microsomes HPLC analysis of 4-hydroxytamoxifen glucuronides formed by human liver microsomes. Human liver microsomes (HLM; 10 µg protein) were incu-
bated at 37°C for 30 min with 25 µM trans-4-hydroxytamoxifen (trans-4-OH-TAM) or 15 µM cis-4-OH-TAM and 4 mM UDP-glucuronic acid prior to 
analysis by HPLC as described in Materials and methods. Propranolol was added to all assays postincubation as an internal standard for HPLC. (a) 
No substrate, internal standard (propranolol) only; (b) nonincubated 70:30 mixture of trans-4-OH-TAM:cis-4-OH-TAM (Sigma); (c) nonincubated 
98% pure trans-4-OH-TAM (Sigma); (d) nonincubated cis-4-OH-TAM purified from the 70:30 mixture shown in (b); (e) trans-4-OH-TAM incubated 
with HLM; (f) cis-4-OH-TAM incubated with HLM; (g) trans-4-OH-TAM incubated with HLM and β-glucuronidase; (h) cis-4-OH-TAM incubated with 
HLM and β-glucuronidase; (i) trans-4-OH-TAM incubated with HLM and 1 N NaOH; (j) cis-4-OH-TAM incubated with HLM and 1 N NaOH. Peak 1, 
propranolol; peak 2, cis-4-OH-TAM; peak 3, trans-4-OH-TAM; peak 4, trans-TAM-4-O-glucuronide (predicted); peak 5, trans-4-OH-TAM-N+-glu-
curonide (predicted); peak 6, cis-TAM-4-O-glucuronide (predicted); peak 7, cis-4-OH-TAM-N+-glucuronide (predicted). mAU, milli-absorbance 
units.Breast Cancer Research    Vol 8 No 4    Sun et al.
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Using propranolol as an internal standard (Figure 1a), the cis
and trans isomers of 4-OH-TAM eluted at retention times of
27.1 minutes and 27.6 minutes, respectively, as shown by
HPLC of a 70:30 mix of trans-4-OH-TAM:cis-4-OH-TAM
(Sigma) (Figure 1b), of 98% pure trans-4-OH-TAM (Sigma)
(Figure 1c), and of cis-4-OH-TAM purified from the 70:30
trans-4-OH-TAM:cis-4-OH-TAM mix (Sigma) (Figure 1d). In
assays with human liver microsomes, two 4-OH-TAM glucuro-
nide peaks with retention times of 18.2 minutes (peak 4) and
23.0 minutes (peak 5) were observed in assays with trans-4-
OH-TAM (Figure 1e), and two 4-OH-TAM glucuronide peaks
with retention times of 18.6 minutes (peak 6) and 22.5 min-
utes (peak 7) were observed in assays with cis-4-OH-TAM
(Figure 1f). Peaks 4–7 were sensitive to treatment with β-glu-
curonidase in glucuronidation assays with either trans-4-OH-
TAM (Figure 1g) or cis-4-OH-TAM (Figure 1h). Only peaks 5
and 7 were sensitive to treatment with alkali after glucuronida-
tion assays with either trans-4-OH-TAM (Figure 1i) or cis-4-
OH-TAM (Figure 1j).
This pattern is similar to that observed for N-glucuronide ver-
sus O-glucuronide deconjugation for other compounds [32] –
suggesting that peaks 4 and 6 corresponded to trans-TAM-4-
O-glucuronide and cis-TAM-4-O-glucuronide, and that peaks
5 and 7 corresponded to trans-4-OH-TAM-N+-glucuronide
and cis-4-OH-TAM-N+-glucuronide in assays with either trans-
4-OH-TAM or cis-4-OH-TAM, respectively. The products cor-
responding to predicted trans-OH-TAM-N+-glucuronide and
cis-4-OH-TAM-N+-glucuronide were analyzed using LC with
electrospray MS detection (Figure 2). The mass spectrum for
the trans-4-OH-TAM-N+-glucuronide showed a clear [M+] ion
at m/z 563.80 (calculated molecular weight, 563.29); a virtu-
ally identical pattern was observed for cis-4-OH-TAM-N+-glu-
curonide, with a clear [M+] ion at m/z  563.70 (data not
shown). These data suggest that the glucuronides derived
from both isomers were in fact monoglucuronides.
In assays with microsomes prepared from wild-type
UGT1A424Pro/48Leu-overexpressing cells, significant glucuroni-
dating activities were observed against both trans-4-OH-TAM
and cis-4-OH-TAM (Figure 3). Single glucuronide peaks were
observed in assays with either substrate (Figure 3a,b), with
these peaks corresponding to the retention times of peaks 5
and 7 in glucuronidation assays with human liver microsomes
(see Figure 1). These peaks were alkali sensitive (Figure 3c,d)
and were sensitive to treatment with β-glucuronidase (results
not shown), suggesting that these glucuronides corresponded
to 4-OH-TAM-N+-glucuronide. Predicted UGT1A4-induced
monoglucuronides were confirmed by LC–MS for both trans-
4-OH-TAM and cis-4-OH-TAM (results not shown). No TAM-
4-O-glucuronide formation was observed in assays with either
the trans or cis isomer of 4-OH-TAM with UGT1A4-overex-
pressing cell microsomes, and no glucuronidation activity was
observed for untransfected HK293 cell homogenates for any
substrate examined in this study (results not shown).
As shown in a concentration curve for both isoforms of 4-OH-
TAM (Figure 4), the rate of UGT1A4-catalyzed glucuronide
formation was fully saturated at approximately 10–15 µM for
trans-4-OH-TAM and cis-4-OH-TAM in our assay conditions.
Using a concentration range of 4-OH-TAM (1–10 µM for
trans-4-OH-TAM and 1–15 µM for cis-4-OH-TAM) and a spe-
cific incubation time (30 min), the apparent Km values and the
Vmax/Km ratios for UGT1A4-induced glucuronidation of trans-
Figure 2
Representative mass spectra of trans-4-hydroxytamoxifen quaternary ammonium glucuronide formed by human liver microsomes Representative mass spectra of trans-4-hydroxytamoxifen quaternary ammonium glucuronide formed by human liver microsomes. The predicted 
trans-4-hydroxytamoxifen quaternary ammonium glucuronide (trans-4-OH-TAM-N+-glucuronide) was collected after separation by HPLC and identi-
fied by liquid chromatography–mass spectrometry using a Shimadzu LC-MS 2010 EV system. trans-4-OH-TAM-N+-glucuronide was loaded onto a 
C18 Shimadzu reverse-phase column and analyzed at a flow rate of 0.2 ml/min by applying a linear mobile phase gradient from 10% to 80% (v/v) 
methanol/H2O over 30 min. An electrospray voltage of 1.5 kV was applied using a positive mode.Available online http://breast-cancer-research.com/content/8/4/R50
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4-OH-TAM and of cis-4-OH-TAM were 2.2 ± 0.4 µM and 29.3
± 2.7 µl/min/µg, and 2.1 ± 0.4 µM and 2.0 ± 0.3 µl/min/µg,
respectively (performed in three independent experiments for
both isomers).
Analysis of TAM and trans-4-OH-TAM, cis-4-OH-TAM 
glucuronidation by human UGT1A4 variants
To determine whether the Pro>Thr amino acid change at
codon 24 or the Leu>Val amino acid change at codon 48
affected UGT1A4 enzyme activity against TAM or 4-OH-TAM
isomers, stable HK293 cell lines overexpressing either the
UGT1A424Thr/48Leu or the UGT1A424Pro/48Val variant isoforms
were created by site-directed mutagenesis using the
pcDNA3.1/V5-His-TOPO plasmid expressing wild-type
UGT1A424Pro/48Leu as a template. Semiquantitative western
blot analysis showed high levels of UGT1A4 protein in micro-
somes prepared from wild-type UGT1A424Pro/48Leu-overex-
pressing and UGT1A424Thr/48Leu-overexpressing or
UGT1A424Pro/48Val-overexpressing HK293 cell lines (Figure 5).
The UGT1A4 expression levels were normalized to the levels
of the endoplasmic reticulum-specific protein, calnexin, in
each lane as measured by densitometry and were determined
against varying amounts of human UGT1A protein (200–300
ng; also measured by densitometry). The results demonstrated
that the level of expression of UGT1A4 in the UGT1A424Thr/
48Leu-overexpressing and UGT1A424Pro/48Val-overexpressing
cell lines was respectively 0.73-fold and 0.81-fold that
observed in the wild-type UGT1A4-overexpressing cell line.
As shown in Table 1, kinetic analysis demonstrated that higher
glucuronidation activities were observed for UGT1A424Pro/
48Val-overexpressing microsomes as compared with micro-
somes from wild-type UGT1A424Pro/48Leu-overexpressing cells
against TAM and against both the trans and cis isomers of 4-
OH-TAM. A significantly (P ≤ 0.02) lower Km value (~1.6-fold
to 1.8-fold) was observed for both 4-OH-TAM isomers, while
a near-significant (P = 0.053) decrease in Km was observed
for TAM – for the UGT1A424Pro/48Val variant compared with
wild-type UGT1A4. The Vmax/Km ratio for the UGT1A424Pro/
48Val variant was significantly (P  ≤ 0.005) higher than that
observed for the wild-type UGT1A4 isoform after normaliza-
tion for UGT1A4 expression by western blotting for both the
Figure 3
HPLC analysis of 4-hydroxytamoxifen glucuronides formed by wild-type UGT1A4-overexpressing cell microsomes HPLC analysis of 4-hydroxytamoxifen glucuronides formed by wild-type UGT1A4-overexpressing cell microsomes. UGT1A424Pro/48Leu-overexpress-
ing cell microsomes (10 µg protein) were incubated at 37°C for 30 min with 25 µM trans-4-hydroxytamoxifen (trans-4-OH-TAM) or 15 µM cis-4-OH-
TAM and 4 mM UDP-glucuronic acid prior to analysis by HPLC as described in Materials and methods. Propranolol was added to all assays postin-
cubation as an internal standard for HPLC. (a) trans-4-OH-TAM incubated with UGT1A4-overexpressing microsomes; (b) cis-4-OH-TAM incubated 
with UGT1A4-overexpressing microsomes; (c) trans-4-OH-TAM incubated with UGT1A4-overexpressing microsomes and 1 N NaOH; (d) cis-4-
OH-TAM incubated with HLM and 1 N NaOH. Peak 1, propranolol; peak 2, cis-4-OH-TAM; peak 3, trans-4-OH-TAM; peak 5, trans-4-OH-TAM-N+-
glucuonide; peak 7, cis-4-OH-TAM-N+-glucuonide (peak numbers consistent with those described for Figure 1). mAU, milli-absorbance units.Breast Cancer Research    Vol 8 No 4    Sun et al.
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trans and cis isomers of 4-OH-TAM. No significant effect on
Figure 4
Concentration curves for 4-hydroxytamoxifen glucuronide formation with microsomes from wild-type UGT1A4-overexpressing cells Concentration curves for 4-hydroxytamoxifen glucuronide formation with microsomes from wild-type UGT1A4-overexpressing cells. Concentration 
curve incubations for trans-4-hydroxytamoxifen (trans-4-OH-TAM) and cis-4-hydroxytamoxifen (cis-4-OH-TAM) glucuronide formation were per-
formed for 30 min at 37°C using 10 µg microsomal protein.
Table 1
Kinetic analysis of UGT1A4-induced glucuronidation of tamoxifen, trans-4-hydroxytamoxifen and cis-4-hydroxytamoxifen
Substrate UGT1A4 variant Vmax value (pmol/min/µg 
UGT1A4 protein)
Km value (µM) Vmax/Km ratio (µl/min/µg 
UGT1A4 protein)
trans-4-Hydroxytamoxifen UGT1A424Pro/48Leu 62.4 ± 5.8 2.2 ± 0.4 29.3 ± 2.7
UGT1A424Thr/48Leu 54.9 ± 11.4 1.6 ± 0.1 33.2 ± 4.9
UGT1A424Pro/48Val 49.3 ± 2.8 1.2 ± 0.1* 40.8 ± 1.4**
cis-4-Hydroxytamoxifen UGT1A424Pro/48Leu 4.1 ± 0.1 2.1 + 0.4 2.0 + 0.3
UGT1A424Thr/48Leu 5.0 + 0.7 2.3 + 0.4 2.2 + 0.5
UGT1A424Pro/48Val 5.6 + 0.2 1.3 + 0.1† 4.4 + 0.4‡
Tamoxifen UGT1A424Pro/48Leu 68.0 ± 8.6 2.0 ± 0.51 35.2 ± 9.6
UGT1A424Thr/48Leu 62.1 ± 2.6 1.5 ± 0.20 41.0 ± 7.0
UGT1A424Pro/48Val 52.1 ± 10.1 1.3 ± 0.10§ 40.1 ± 7.5
Data are expressed as the mean ± standard deviation for three independent experiments. Values are significantly (*P = 0.01, **P = 0.005, †P = 
0.02, ‡P = 0.001) or near-significantly (§P = 0.053) higher than that observed for microsomes from wild-type UGT1A424Pro/48Leu-overexpressing 
cells.Available online http://breast-cancer-research.com/content/8/4/R50
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enzyme kinetics was observed for the UGT1A424Thr/48Leu vari-
ant against either isomer of 4-OH-TAM or against TAM itself.
Discussion
The present study is the first to examine the potential role of
UGT genetic polymorphisms on the metabolism of TAM and
its active metabolites. Limited studies have previously been
reported identifying the UGT enzymes involved in TAM metab-
olism. The hepatic UGT2B15 was shown to be the major UGT
active against cis-4-OH-TAM, while a second hepatic UGT
(UGT1A4) was suggested to possess limited activity against
both the cis and trans isomers of 4-OH-TAM [29]. In more
recent studies [30], UGT1A4 was shown to be the only active
UGT against TAM, forming a quarternary ammonium-linked
glucuronide with TAM's N, N-dimethylaminoalkyl side chain.
The fact that UGT1A4 was shown to be active against TAM is
not surprising given that this activity is consistent with
UGT1A4's activity spectrum to produce N-glucuronidated
metabolites with other compounds [31-34,39-41].
To better characterize the glucuronide specificity of UGT1A4
against 4-OH-TAM in the present study, HPLC assays were
conducted using UGT1A4-overexpressing cells. In this study,
UGT1A4 exhibited significant activity with very low apparent
Km values against both trans-4-OH-TAM and cis-4-OH-TAM.
The single glucuronide peaks observed for incubations of
UGT1A4-overexpressing microsomes with either trans-4-OH-
TAM or cis-4-OH-TAM were sensitive to alkali as well as to β-
glucuronidase, suggesting that these glucuronides corre-
sponded to 4-OH-TAM-N+-glucuronide. This pattern of glu-
curonide formation was similar to that observed in human liver
microsomes, where both the TAM-4-O-glucuronide and the 4-
OH-TAM-N+-glucuronide were detected in incubations with
either the trans or cis isomers of 4-OH-TAM, with the peaks
corresponding to 4-OH-TAM-N+-glucuronide sensitive to
treatment with alkali and β-glucuronidase. Both trans-4-OH-
TAM-N+-glucuronide and cis-4-OH-TAM-N+-glucuronide
peaks were confirmed by LC–MS to be 4-OH-TAM monoglu-
curonides.
These data suggest that – identical to previous observations
for TAM [30], and as in recent studies by Ogura and col-
leagues [42] for 4-OH-TAM – UGT1A4 forms a quarternary
ammonium-linked glucuronide with the N,  N-dimethylami-
noalkyl side chain of 4-OH-TAM. This activity is consistent with
UGT1A4's activity spectrum to produce N-glucuronidated
metabolites with other compounds [31-34,39-41].
The  Km values reported in the present study for wild-type
UGT1A4-induced glucuronidation of trans-4-OH-TAM and
cis-4-OH-TAM were 2.2 µM and 2.1 µM, respectively. These
values are 35-fold lower than that observed previously for
UGT1A4 against the trans and cis isoforms of 4-OH-TAM
[29]. The differences in kinetic data observed between studies
for the same enzyme may be due to the fact that a baculosome
overexpression system was used in the analysis of UGT1A4 in
previous studies while microsomes from UGT1A4-overex-
pressing cells were used for the present study.
While trans-4-OH-TAM exhibits approximately 100 times the
level of antiestrogenic activity compared with nonmetabolized
tamoxifen and is probably a significant contributor to overall
TAM-associated antiestrogenic activity [16-21], its desmethyl
derivative, endoxifen, exhibits roughly the same antiestrogenic
activity as 4-OH-TAM, but appears to be more abundant than
4-OH-TAM in the serum of TAM-treated women [19,43,44].
Studies examining the glucuronidation of endoxifen have not
yet been performed, but, unlike TAM and 4-OH-TAM, the N
position on endoxifen is demethylated, suggesting that
endoxifen may perhaps be a less effective substrate for N-glu-
curonidation by enzymes such as UGT1A4. Studies aimed to
identify the UGTs that are active against endoxifen are cur-
rently ongoing.
The two previously identified missense UGT1A4 polymor-
phisms examined in this study are located at codons 24 and
48, resulting in Pro>Thr and Leu>Val amino acid changes,
respectively [35,36]. The codon 24 polymorphism, which was
previously linked to increased glucuronidation activity against
the tobacco-specific nitrosamine 4(methylnitro-
samino)1(3pyridyl)1butanol [36] in in vitro assays using indi-
vidual human liver microsomes, exhibited no association with
altered glucuronidation capacity in vitro for 4-OH-TAM or for
TAM in the present study. This pattern is also different from the
apparent decrease in activity observed for this variant against
β-naphthylamine, benzidine, trans-androsterone and dihy-
drotestosterone, although statistical analysis for glucuronida-
tion rates between variants against each of these compounds
were not provided in these studies [35]. This suggests that the
Figure 5
Western blot analysis of UGT1A4 protein from UGT1A4-overexpress- ing cell lines Western blot analysis of UGT1A4 protein from UGT1A4-overexpress-
ing cell lines. Equal amounts (20 µg) of microsomal protein were 
loaded for each lane. The amount of UGT1A4 expression was normal-
ized against the levels of calnexin in each lane and was quantified by 
densitometry relative as described in Materials and methods. Untrans-
fected HK293 cell protein was analyzed as a negative control for UDP-
glucuronosyltransferase detection.Breast Cancer Research    Vol 8 No 4    Sun et al.
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functional effects of the UGT1A4 codon 24 polymorphism
may be substrate dependent. Alternatively, in vitro functional
analysis of the codon 24 polymorphism using a cell-line-over-
expression system may not be optimal for studies of its effect
on glucuronidation kinetics. A significant association was,
however, observed for the UGT1A4 codon 48 polymorphism
and 4-OH-TAM glucuronidation. The increased activity
observed for the UGT1A424Pro/48Val variant as compared with
the wild-type UGT1A424Pro/48Leu isoform against trans-4-OH-
TAM, cis-4-OH-TAM and TAM suggests that the codon 48
polymorphism may significantly alter UGT1A4 enzymatic func-
tion against TAM and its active metabolites. As it is not yet
clear whether UGT1A4 is active against endoxifen, the role of
the UGT1A424Pro/48Val variant on endoxifen glucuronidation is
presently not known.
Previous studies have demonstrated that variant genotypes for
enzymes involved in the TAM metabolism may significantly
alter overall patient response to TAM. The low-activity
SULT1A1*2 allele was linked to increased rates of mortality in
breast cancer patients treated with TAM [45]. In addition, the
use of antidepressants, which act to inhibit CYP2D6, resulted
in significantly smaller reductions in plasma hydroxylated TAM
metabolite levels in TAM-treated patients with a variant
CYP2D6 genotype [19,43], supporting a role for the CYP2D6
genotype in overall patient response to TAM. Variant, low-
activity/expression alleles in CYP2D6, CYP2B6 and CYP2C9
were similarly correlated with levels of trans-4-OH-TAM forma-
tion in human liver microsomes from individual subjects [46].
The data presented in the present report. suggest that sub-
jects with the UGT1A424Pro/48Val variant could potentially be
similarly impacted with respect to individual patient response
to TAM treatment and TAM-related toxicities. The prevalence
of the UGT1A424Pro/48Val variant is relatively high (9.5% in a
German Caucasian population [35]) so this could impact a rel-
atively large percentage of the population given the large
number of women being treated with TAM, with approximately
19% of Caucasian females expected to have at least one
UGT1A424Pro/48Val variant allele. Long-term studies examining
patient response to TAM and TAM-induced toxicities versus
UGT1A4 genotypes will be necessary to more fully evaluate
the role of UGT genotypes on TAM therapeutic efficacy.
Conclusion
Results from this study indicate that UGT1A4 exhibits very
high activity against TAM and against both isomers of 4-OH-
TAM, and that the UGT1A4 codon 48 polymorphic variant is
associated with altered TAM and 4-OH-TAM glucuronidation
activities. These studies suggest that subjects with the
UGT1A424Pro/48Val  variant could potentially be similarly
impacted with respect to individual patient response to TAM
treatment and TAM-related toxicities.
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